OncoMatch/Clinical Trials/NCT04271644
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Is NCT04271644 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BCMA CAR-T cells for multiple myeloma.
Treatment: BCMA CAR-T cells — This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) any tested (cell membrane BCMA expression)
Evidence for cell membrane BCMA expression
Disease stage
Required: Stage RELAPSED, REFRACTORY
Prior therapy
Must have received: chemotherapy
Failed to standard chemotherapy regimens
Must have received: hematopoietic stem cell transplant
Relapse after hematopoietic stem cell transplantation
Lab requirements
Kidney function
creatinine clearance≤2 x uln
Liver function
alt/ast≤3 x uln and bilirubin≤2 x uln
Cardiac function
left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify